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Background Asthma in the elderly seems to be  more severe compared to asthma in younger 
patients, with a possible reduced responsiveness to  treatment. The aim of this study was to 
evaluate long-term effects of Omalizumab in elderly asthmatics in a real-life setting. 
Methods: 105 consecutive severe asthmatics (step 4-5 according to GINA criteria; mean 
FEV1:66±15.7%) on treatment with Omalizumab for at least 1 year (mean 35.1±21.7 months) were 
included into the study and  divided into 3 groups according to the age at the onset of 
Omalizumab treatment: 18-39, 40-64 and ≥65 years.  
Results: Older subjects differed from the other groups for number of comorbidities, prevalence of 
overweight/obese subjects and for later asthma onset. A significant and similar reduction of 
controller therapy  and use of SABA on demand was observed  in the three groups during 
omalizumab therapy. FEV1  increased significantly and similarly in all the groups. Asthma Control 
Test (ACT) improved significantly (p < 0.001) in the three groups , increasing from 15 [12-18] to 24 
[22-25] in the younger, from  14 [10-16] to 21 [20-23] in the 40-64 years group and from 15 [12-
16] to  20 [18-22]  in the elderly, the improvement being lesser than in the other groups (p = 
0.039). The decrease in asthma exacerbation was significant in all the groups, but the percentage 
of patients free of exacerbations was higher in the younger (76.9%) compared to middle aged 
patients (49.2%) and elderly(29%) (p=0.049).  
Conclusion: Omalizumab  improved all asthma outcomes independently of age, but the magnitude 






Severe asthma is defined as the requirement for high-intensity treatment to obtain a disease 
control (1). However, despite using high doses of inhaled corticosteroids (ICS), bronchodilators and 
anti-leukotriens, we sometimes fail to achieve asthma control. In this case, adding Omalizumab to 
treatment permits us to improve the disease control. In fact, Omalizumab (Xolair®) is a 
recombinant DNA-derived humanized monoclonal antibody indicated as an add-on therapy in 
patients aged ≥ 6 years with severe persistent allergic asthma uncontrolled at treatment step 4 or 
5 according to guidelines GINA (2). Omalizumab demonstrated to be efficacious both in adults and 
children (3-5). In particular, in real-life studies, anti-IgE therapy showed short- and long-term 
benefits in terms of improving lung function and quality of life, achieving asthma control and 
reducing symptomatology, severe exacerbations, healthcare resource utilizations, hospitalizations, 
emergency department visits and reducing or discontinuing other asthma medications thus 
confirming, complementing, and extending evidence from randomized trials (3,5). 
However, in the various studies performed to test the effectiveness of Omalizumab, elderly 
patients are under-represented. Therefore, it is not well clear if Omalizumab is able to improve 
significantly asthma control in severe asthmatics older than 65 years. Only one study observed an 
improvement of asthma outcomes after a short follow-up (4 months) of Omalizumab treatment in 
asthmatics older than 50 years similarly to patients younger than 50 years (6). However, the doubt 
about  Omalizumab effectiveness in patients older than 65 years, above all in the long term, still 
remains. In fact, there are data suggesting that asthma in older adults is phenotypically different 
from asthma in younger patients. Some pathophysiological mechanisms of elderly asthma are 
different from those seen in young asthmatics and these differences may influence the clinical 
course, asthma outcomes and treatment response in this population. In fact, the elderly have 
lower post-bronchodilator FEV1%, more exacerbations and risk of first severe exacerbation is 
increased by 55.3% when compared to younger patients (7). Asthma in the elderly seems to 
represent a specific phenotype characterized by more severe, but often less perceived, airway 
obstruction, a neutrophilic or mixed-type of airway inflammation and frequent comorbidities (8,9). 
Older asthmatics are often characterized by long-standing asthma that has more severe airflow 
limitation and less complete reversibility (or even irreversibility) than in patients with late-onset 
asthma (10). In fact, airways remodeling and a possible coexisting COPD can determine a greater 
asthma severity in the elderly (11). Older patients with asthma have significantly increased 
percentages of sputum neutrophils (12). This pattern is a characteristic of intrinsic asthma with 
neutrophilic inflammation that may be associated to a more severe obstructive disease and a poor 
response to treatment (8-10). In addition, elderly subjects usually have multiple chronic illnesses 
that can be also associated with poor asthma outcomes (13-15). Therefore, severe asthma in the 
elderly may be more serious and thus more difficult to treat in comparison to severe asthma in 
younger patients. Likely, the advanced age itself may also influence the response to Omalizumab. 
Therefore, the aim of this study was to assess the effectiveness of long-term Omalizumab 
treatment in a  real-life setting in patients over 65 with severe uncontrolled asthma. 
Materials and Methods 
Eighteen Italian Asthma Units were involved in this retrospective study. Data of at least 3 
consecutive severe asthmatics (step 4-5 according to GINA criteria) (2) in treatment with 
Omalizumab, for at least 1 year, were requested from each Center. All recruited patients should 
have shown a poor disease control with an ICS therapy associated to long-acting bronchodilators 
and Montelukast for which it was necessary to add Omalizumab. Data were extracted from each 
patient's clinical record and recorded in a previously agreed form. Information relative to 
demographic data, allergic sensitization (Dermatofagoides pteronissinus and D. farinae, Grass mix, 
Parietaria, Olea europaea, Cupressus sempervirens, Betula pendula, Alternaria tenuis, Aspergillus f. 
and dog-cat dander), IgE values, the presence of rhinitis, sinusitis, nasal polyposis, other 
comorbidities (hypertension, chronic heart disease, diabetes, osteoporosis, gastro-esophageal 
reflux, COPD, obesity), smoking habits and body mass index (BMI) obtained before the onset of 
Omalizumab treatment were required for each patient. Furthermore, age of asthma onset, 
Omalizumab dosing and period of treatment with anti-IgE were required in the form. For the 
purpose of the study, the evaluation, before and after Omalizumab treatment, of FEV1, FEV1/FVC, 
Asthma Control Test (ACT), number of moderate/severe exacerbations registered in the previous 
year, ICS doses, treatments with LABA,LAMA, Montelukast and how many times a week SABA (as 
rescue medication) was used, were also considered. It was also evaluated if the treatment was in 
general stable or reduced after using Omalizumab. The period of data collection was November 
2014 – November 2015. At the end of such period, 105 severe asthmatics were recruited.  
For the objective of our study, these patients were divided into 3 groups on the basis of age 
observed at the onset of Omalizumab treatment: subjects aged 18-39, 40-64 and ≥65 years. Then 
all data of each group were compared.  
Exacerbations that required systemic corticosteroids for at least 3 days and/or hospitalizations 
were taken into account. Obesity was defined by a BMI > 30. The use of ICS with daily dosage was 
expressed as low (≤500 µg), medium (500-1000 µg) or high (≥1000 µg) dosage of beclomethasone 
dipropionate, CFC or equivalent according to GINA classification (2). The number of exacerbations 
and daily dosage of ICS reported in the year before using Omalizumab and during the last year of 
treatment with anti-IgE (before our study) were considered. The use of SABA (number of times a 
week) in the month before starting Omalizumab and before the beginning of this study was also 
taken into account. As regards comorbidities, only those which had a documented evidence were 
considered. Diagnosis of asthma-COPD overlap was established when, in presence of chronic 
cough/phlegm and smoking history, hyperinflation and reduced single breath CO diffusion test 
(DLCO) <80% was assessed by spirometry and/or central-panlobular emphysema was seen by high 
resolution computed tomography. 
 
Statistical Analysis 
Continuous variables were expressed as mean and standard deviation (SD) or median and 
interquartile [IQR] range. Categorical variables were expressed as number of cases and 
percentages.  
Comparison of continuous variables among the age groups was performed by using the Kruskal–
Wallis test. The Wilcoxon signed-rank test was used to assess the difference between "before" and 
"after" treatment. The categorical variable frequencies were compared by chi-square test or 
Fisher's exact test, as appropriate. A logistic binary regression model, corrected for sex, BMI, FEV1, 
sensitizations, IgE value, comorbidities, smoking, age of asthma onset, Omalizumab treatment 
duration, daily dose of ICS and montelukast use, was applied with the purpose to test if zero 
setting of exacerbations was an independent and different risk factor in the various age brackets 
(18-39,40-64 and ≥65 years). Furthermore, a linear regression model, corrected for all parameters, 
above reported, was also performed to test if ACT changes after Omalizumab treatment were 
independently related to the three classes of age considered (18-39,40-64 and ≥65 years). 
. 




Asthmatics aged between 18 and 39 years were 13 (12.4% of all patients; mean FEV1: 67.2±12.4%), 
whereas patients aged between 40 and 64 years were 61 (58.1% of all patients; mean FEV1: 
65.6±16%) and those aged ≥65 years were 31 (29.5% of all patients; mean FEV1: 66.2±16.7%). In 
Table 1, are reported and compared data observed in the three groups with different ages. BMI 
resulted higher (p=0.049) in subjects with medium and older age. No difference in number of 
allergen sensitizations was found in three groups. Furthermore, no differences were observed in 
total IgE values (evaluated before beginning the Omalizumab therapy), doses and time (months) of 
anti-IgE drug treatment. Also the number of subjects in treatment with ICS, long-acting 
bronchodilators and montelukast (used before adding Omalizumab) was similar in the three 
groups. Anyhow, the number of asthmatics with more comorbidities was obviously higher in those 
with older age. 
In figure 1 are reported median FEV1% values measured before (pre) and after (post) adding 
Omalizumab. Percentage pre-values (70 [60-76.6]; 68 [55-75]; 67 [58-79]; p=0.838; figure 1/A) and 
post-values (82.1 [73-88]; 82 [66-93]; 80 [71-92]; p=0.906; figure 1/B) measured in asthmatics with 
younger, medium and older age (respectively) were similar. Whereas, FEV1 values, measured after 
treatment with Omalizumab, improved significantly (p<0.001; comparing pre-post) and similarly in 
each group. Also ACT values (figure 2), measured after Omalizumab treatment, improved 
significantly (p<0.001; comparing pre-post – figure 2 A and B) in each group (pre values: 15 [12-
18]; 14 [10-16]; 15 [12-16]; post-values: 24 [22-25]; 21 [20-23]; 20 [18-22]; measured in subjects 
with younger, medium and older age respectively). However, the improvement of ACT observed 
after Omalizumab was lower in asthmatics over 65 years (20 [18-22]) when compared with 
younger subjects aged 18-39 years (24 [22-25]; p=0.039; figure 2).  
There was a significant reduction in the number of exacerbations after Omalizumab treatment in 
each group (Figure 3; p<0.0001). The number of exacerbations recorded before the ant-IgE 
treatment was similar in the three groups, but different after Omalizumab treatment. In fact, no 
exacerbations were obtained in 76.9% of younger subjects, in 49.2% of patients with medium age 
and only in 29% of older asthmatics (p=0.049). ICS doses decreased significantly and similarly after 
anti-IgE treatment in each group (p<0.01; figure 3). We also observed a significant and similar 
reduction of SABA used as a rescue medication in all groups (Figure 4). 
Having found a difference in number of exacerbations among 3 groups, we applied a logistic 
model considering as dependent variable zero setting of exacerbations corrected for sex, 
BMI,FEV1, sensitizations, IgE value, comorbidities, smoking habits, age of asthma onset, 
Omalizumab treatment duration, daily doses of ICS and montelukast use. Younger subjects 
showed a significantly higher odd ratios to develop zero exacerbations (subjects aged 40-64: 3.52 
[1.21-10.23], p=0.021; subjects aged 18-39: 7.52 [1.47-38.39], p=0.015) in comparison to subjects 
over 65 years. In addition, having found a lower ACT increase in the elderly, we applied a linear 
regression model (corrected for all the above said variables) to evaluate the relationship among 
the three different classes of age and the change of ACT obtained after Omalizumab. In 
confirmation to what observed above, we found a significantly reduced increase of ACT (-1.070; 
p=0.046) passing from one class of age to the other, independently of all the confounding 
variables.  
Discussion 
According to our long-term real-life study, Omalizumab has demonstrated to be efficient in 
improving asthma outcomes in all age brackets of uncontrolled severe asthmatics. In fact, FEV1 
and ACT increased whereas, exacerbations, ICS dosage and SABA used as rescue medications 
decreased significantly after approximately a 3-year Omalizumab treatment in all groups, 
independently of age.  
However, a reduced improvement in ACT and a lower rate of asthmatics without exacerbations in 
the previous year were found in elderly asthmatics, when compared to younger patients, after a 
long-term treatment with Omalizumab. In addition, a previous real-life study found that 24% of 
asthmatics patients in treatment with Omalizumab showed a poor asthma control (16). These 
subjects were older when compared to well-controlled asthmatics, confirming that just the elderly 
may have a more difficult control of the disease even with Omalizumab. This would suggest a 
reduced response to treatment in elderly patients or a more severe asthma more difficult to treat 
in these categories of subjects. There is no clear evidence supporting a lower efficacy of asthma 
therapies in older subjects (7,17), whereas it is more probable that a poor response may depend 
on a different asthma phenotype in the elderly, characterized by a greater disease severity. In fact, 
according to our study, asthmatics over 65 years, showed a higher BMI (more numerous 
overweight/obese subjects), a greater number of comorbidities and a more advanced asthma 
onset age, when compared to younger subjects. These different characteristics may increase 
disease severity and therefore reduce the response to treatment in the elderly. In fact, 
overweight/obese status, with an increased subcutaneous and visceral abdominal fat mass, which 
is a characteristics of elderly subjects, is a risk factor for a higher airway hyperresponsiveness 
(AHR), lung function decline and risk of asthma (18-24). Furthermore, in obesity, lung volume and 
tidal volume are reduced, thus promoting airway narrowing (20,24,25). Obesity also leads to a 
state of low-grade systemic inflammation (increased leptin, TNF-α, IL-6, TGF- β1, adiponectin and 
C-reactive protein) that may act on the lungs to aggravate asthma (24,25). In fact, the proportion 
of obese subjects increased with asthma severity step, reaching the peak in the highest asthma 
severity step (26). Furthermore, several studies showed an inverse relationship between BMI 
categories and reduction in asthma control, in response to all controller therapies (ICS, 
antileukotrienes and ICS plus long-acting β agonist in combination) (25-29). Therefore, obesity can 
be an important factor that may have influenced the reduced response to Omalizumab in the 
elderly asthmatics of our study in terms of ACT level and number of exacerbations.  
In addition, overweight and obesity are associated to other comorbidities (glucose intolerance, 
dyslipidemia, hypertension, type 2 diabetes, kidney failure, osteoarthritis, others) which can lead, 
in general, to further morbidity and mortality (30). The comorbidity burden is significantly 
associated with asthma-related quality of life, unscheduled asthma care, emergency department 
visit, asthma hospitalization, or the 30-day fatality rate following asthma hospitalization (15). 
Furthermore, comorbidities are associated with an ageing population; they negatively affect 
health outcomes and are associated with asthma in these subjects (8-10). In fact, according to our 
study, comorbidities such as hypertension, chronic heart disease, diabetes, gastro-esophageal 
reflux and osteoporosis are more prevalent in old age, making the disease more severe thus 
influencing the reduced response to treatment with Omalizumab in the elderly. In confirmation, 
some researches have shown that poor asthma control, measured as reduced ACT, was associated 
with asthma-related comorbid diseases in real-life (13,16,31).  
In particular, we observed an increased number of elderly subjects affected by hypertension that 
may be a marker of asthma severity in older asthmatic patients. In fact, according to recent 
studies (32), asthmatic subjects with comorbid hypertension display evidence of enhanced asthma 
morbidity. 
Another aspect of our study is the proof that asthma onset age was higher in older subjects and 
that it may have induced the lower efficacy of Omalizumab. Asthma onset age is used to 
distinguish different adult asthma phenotypes. Asthma starting in adulthood differs from 
childhood-onset as regards asthma high symptom scores, poor quality of life, the need for high-
intensity treatment, low/fixed lung function and high exacerbation rate. Furthermore, patients 
with severe adult-onset asthma are more often females, non-atopic, with more nasal symptoms, 
nasal polyposis, higher exhaled nitric oxide levels, blood neutrophil counts and sputum 
eosinophilia (33,34). All these features, different in younger subjects, may explain the reduced 
effect of Omalizumab in the elderly. Actually, the development of late-onset adult asthma may be 
also the clinical consequence of immunosenescence that would lead to decline in functionality of 
the immune system with increasing age (35-38). This age-related process determines a progressive 
impaired mucociliary clearance, changes in airway neutrophil, eosinophil, and mast cell numbers 
and function over an altered antigen presentation and decreased specific antibody responses (37). 
Furthermore, this immunosenescence and its associated chronic low grade systemic "inflamm-
aging" may contribute to the development and progression of pulmonary disease in older 
individuals (34,37). Therefore, immunosenescence may favor a neutrophilic inflammation that 
determines a more severe disease and less effective asthma treatments in the elderly (38). In our 
study, we found that aging was negatively related to Omalizumab treatment response in terms of 
increase in ACT and reduction of exacerbations after therapy, independently to all confounder 
factors considered by this study: sex, BMI, FEV1, sensitizations, IgE value, comorbidities, smoking 
habits, age of asthma onset, Omalizumab treatment duration, daily doses of ICS and montelukast 
use. This suggest that a reduced response to treatment in the elderly may be simply due to a 
“senescence process” progressing with aging, independently of other factors, that favour a more 
severe asthma development through an immunological/inflammatory process different from the 
one seen in younger asthmatics. Therefore, comorbidities may be part of a global “senescence 
process” together with other pulmonary diseases. According to this concept, comorbidity and 
asthma should only be associated as one is not the cause of the other.  
In conclusion, adding Omalizumab can improve uncontrolled step-4/5 asthma in a real-life setting 
independently of age. However, improvement may be lower in the elderly. This poorer response 
to Omalizumab treatment may be due to an association with comorbidities, in particular 
hypertension and overweight/obese status, and to a more advanced asthma onset age. On the 
other hand, just the “senescence process” (progressive with age) may be responsible for the lower 
efficacy of Omalizumab in the elderly. 
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Table and Figures Legends 
 
Table 1: Comparisons of all variables, measured before the treatment with Omalizumab, among 
the three groups with different age. 
Figure 1: FEV1 values measured before (Pre) and after (Post) Omalizumab treatment. 
Comparison between Pre and Post Omalizumab treatment in subjects aged 18-39 years: p=0.002; in subjects aged 40-64 years: 
p=0.0001; in subjects aged ≥65 years: p=0.0001. 
Comparisons among subjects with different ages: pre-values p=0.838; post-values: p=0.906 
 
Figure 2: Asthma Control Test (AC) values measured before (Pre) and after (Post) Omalizumab 
treatment. 
Comparison between Pre and Post Omalizumab treatment in subjects aged 18-39 years:p=0.001; in subjects aged 40-64 years: 
p=0.0001; in subjects aged ≥65 years: p=0.0001. 
Comparisons among subjects with different ages: pre-values p=0.383; post-values p=0.039. 
 
Figure 3: Prevalence of subjects with different numbers of exacerbations observed in the year 
before (pre) and in the last year (post) of Omalizumab treatment in the 3 groups with different 
ages. 
Comparisons (test di Wilcoxon) of prevalence observed before and after treatment with Omalizumab: p=0.021 between pre-and 
post-treatment in subjects aged 18-39 years; p=0.001 between pre-and post-treatment in subjects aged 40-64 years; p=0.0001 
between pre-and post-treatment in subjects aged ≥65 years 
Comparisons (χ
2
 test) of prevalence observed in subjects with different ages, before (p=0.898) and after (p=0.049) treatment with 
Omalizumab. 
 
Figure 4: Prevalence of subjects treated with different ICS levels used before (pre) and after (post) at least 
1 year of Omalizumab in the 3 groups with different ages 
Low dose of ICS: <500 µg equivalent to bechlometasone; Medium dose of ICS: 500-1000 µg  equivalent to bechlometasone; High 
dose of ICS: >1000 µg equivalent to bechlometasone 
Comparisons (test di Wilcoxon) of prevalence observed before and after treatment with Omalizumab: p=0.057 between pre-and 
post-treatment in subjects aged 18-39 years; p=0.0001 between pre-and post-treatment in subjects aged 40-64 years; p=0.001 
between pre-and post-treatment in subjects aged ≥65 years 
Comparisons (χ
2
 test) of prevalence observed in subjects with different age, before (p=0.369) and after (p=0.757) treatment with 
Omalizumab. 
 
Figure 5: Prevalence of subjects according to how often they used SABA (short-acting β2-agonists) each 
week as a rescue medication reported in the month before (pre) Omalizumab treatment and in the month 
before (post) the beginning of this study in the 3 groups with different ages. 
Comparisons (test di Wilcoxon) of prevalence observed before and after treatment with Omalizumab: p=0.021 between pre-and 
post-treatment in subjects aged 18-39 years; p=0.0001 between pre-and post-treatment in subjects aged 40-64 years; p=0.0001 
between pre-and post-treatment in subjects aged ≥65 years 
Comparisons (χ
2
 test) of prevalence observed in subjects with different age, .before (p=0.631) and after (p=0.641) treatment with 
Omalizumab  
 
 
